Pandemic influenza A (H1N1) 2009: The experience of the first six months

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 1, 2010, Pages 11-21

  Maritz, Jean ^a   Maree, Leana ^a   Preiser, Wolfgang ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

H1N1; Influenza A virus; Pandemic; Review; Swine flu

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; ZANAMIVIR;

AGE DISTRIBUTION; ANTIVIRAL RESISTANCE; CLINICAL FEATURE; COMORBIDITY; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; EXPERIENCE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEALTH SERVICE; HIGH RISK POPULATION; HOSPITALIZATION COST; HUMAN; IMMUNITY; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS A H1N1; INTENSIVE CARE; LABORATORY DIAGNOSIS; MORTALITY; NONHUMAN; PANDEMIC; PATHOGENESIS; PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; VACCINATION;

AGE DISTRIBUTION; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; SURVIVAL RATE;

INFLUENZA A VIRUS; SUIDAE;

EID: 74549221388     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.023     Document Type: Review

References (79)

1. World Health Organization. Influenza-like illness in the United States and Mexico, 24 April 2009. http://www.who.int/csr/don/ 2009-04-24/en/index.html.
2. World Health Organization. Transcript of statement by Margaret Chan, Director-General of the World Health Organization, 11 June 2009. http://www.who.int/mediacentre/influenzaAH1N1- presstranscript-20090611.pdf.
3. World Health Organization. Transcript of Virtual Press Conference, 7 July 2009. http://www.who.int/mediacentre/Pandemic- h1n1-presstranscript-2009-07-07. pdf.
4. World Health Organization. Pandemic influenza (H1N1) 2009-Update 75. http://www.who.int/csr/don/2009-11-20a/en/ index.html.
5. Webby RJ, Webster RG. Emergence of influenza A viruses. Philos Trans R Soc Lond B Biol Sci 2001;356:1817-1828
6. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. http://www.who.int/csr/disease/avian- influenza/country/cases- table-2009-09-24/en/index.html.
7. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, et al. INERWorking Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009;361:680-689
8. Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa- Perez L, de la Torre A, et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. J Am Med Assoc 2009;302:1880-1887
9. World Health Organization. Clinical features of severe cases of pandemic influenza-pandemic (H1N1) 2009 briefing note 13. http://www.who.int/csr/disease/ swineflu/notes/h1n1-clinical- features-20091016/en/index.html.
10. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459:1122-1125
11. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 2009;325:197-201.
12. World Organization for Animal Health (OIE). Evolution of pandemic H1N1 2009 in animals. http://www.oie.int/eng/press/ en-091104.htm.
13. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459:931-939
14. Matrosovich M, Stech J, Klenk HD. Influenza receptors, polymerase and host range. Rev Sci Tech 2009;28:203-217
15. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009;460:1021-1025
16. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, et al. Transmission and pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice. Science 2009;325:484-487
17. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, Bestebroer TM, et al. Pathogenesis and transmission of swine-origin 2009 A (H1N1) influenza virus in ferrets. Science 2009;325:481-483
18. Han K, Zhu X, He F, Liu L, Zhang L, Ma H, et al. Lack of airborne transmission during outbreak of pandemic (H1N1) 2009 among tour group members, China, June 2009. Emerg Infect Dis 2009;15:1578-1581
19. Mauad T, Hajjar LA, Callegari GD, da Silva LF, Schout D, Galas FR, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2009. doi:10.1164/rccm.200909-1420OC.
20. Munayco CV, Gomez J, Laguna-Torres VA, Arrasco J, Kochel TJ, Fiestas V, et al. Epidemiological and transmissibility analysis of influenza A (H1N1)v in a southern hemisphere setting: Peru. Euro Surveill 2009;14. pii: 19299. http://www. eurosurveillance.org/ViewArticle.aspx?ArticleIds19299.
21. Nishiura H, Wilson N, Baker MG. Estimating the reproduction number of the novel influenza A virus (H1N1) in a southern hemisphere setting: preliminary estimate in New Zealand. N Z Med J 2009;122:73-77
22. Nishiura H, Castillo-Chavez C, Safan M, Chowell G. Transmission potential of the new influenza A (H1N1) virus and its age-specificity in Japan. Euro Surveill 2009;14. pii: 19227. http://www.eurosurveillance.org/ViewArticle.aspx? ArticleIds 19227.
23. Chowell G, Miller MA, Viboud C. Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiol Infect 2008;136:852-864
24. Odaira F, Takahashi H, Toyokawa T, Tsuchihashi Y, Kodama T, Yahata Y, et al. Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A (H1N1)v outbreak in Kobe, Japan, May-June 2009. Euro Surveill 2009;14. pii: 19320. http:// www.eurosurveillance.org/ViewArticle.aspx?ArticleIds19320.
25. World Health Organization. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Weekly Epidemiological Record 2009;84:249-257 http://www.who.int/wer/ 2009/wer8425/en/index.html.
26. Centers for Disease Control and Prevention. Introduction and transmission of 2009 pandemic influenza A (H1N1) virus-Kenya, June-July 2009. MMWR 2009;58:1143-1146 http:// www.cdc.gov/mmwr/preview/mmwrhtml/mm5841a1.htm.
27. Ferguson NM, Cummings DA, Cauchemez S, Fraser C, Riley S, Meeyai A, et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005;437:209-214
28. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006;442:448-452
29. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-1952
30. Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 2009; 14. pii: 19288. http://www.eurosurveillance. org/ViewArticle. aspx?ArticleIds19288.
31. Centers for Disease Control and Prevention. Serum crossreactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR 2009;58:521-524 http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5819a1.htm.
32. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-2615
33. Gomez J, Munayco C, Arrasco J, Suarez L, Laguna-Torres V, Aguilar P, et al. Pandemic influenza in a southern hemisphere setting: the experience in Peru from May to September, 2009. Euro Surveill 2009;14. pii: 19371. http://www.eurosurveillance. org/ViewArticle.aspx?ArticleIds19371.
34. Archer B, Cohen C, Naidoo D, Thomas J, Makunga C, Blumberg L, et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill 2009; 14. pii: 19369. http://www.eurosurveillance.org/ViewArticle. aspx?ArticleIds19369.
35. Baker MG, Wilson N, Huang QS, Paine S, Lopez L, Bandaranayake D, et al. Pandemic influenza A (H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill 2009;14. pii: 19319. http://www.eurosurveillance.org/ ViewArticle.aspx?ArticleIds19319.
36. New South Wales public health network. Progression and impact of the first winter wave of the 2009 pandemic H1N1 influenza in New South Wales, Australia. Euro Surveill 2009; 14. pii: 19365. http://www.eurosurveillance.org/ ViewArticle. aspx?ArticleIds19365.
37. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Canadian critical care trials group H1N1 collaborative. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. J Am Med Assoc 2009;302:1872-1879
38. ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009;361:1925-1934
39. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. 2009 Pandemic influenza A (H1N1) virus hospitalizations investigation team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361:1935-1944
40. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009;360:2616-2625
41. World Health Organization. Clinical management of human infection with pandemic (H1N1) 2009: revised guidance. http:// www.who. int / csr / resources / publications / swineflu / clinical- management-h1n1.pdf.
42. Keren R, Zaoutis TE, Bridges CB, Herrera G, Watson BM, Wheeler AB, et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection. J Am Med Assoc 2005;294:2188-2194
43. Ampofo K, Gesteland PH, Bender J, Mills M, Daly J, Samore M, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006;118:2409-2417
44. Jamieson DJ, Theiler RN, Rasmussen SA. Emerging infections and pregnancy. Emerg Infect Dis 2006;12:1638-1643
45. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998;148:1094-1102
46. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al. Novel Influenza A (H1N1) Pregnancy Working Group. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009;374: 451-458
47. Mangtani P, Mak TK, Pfeifer D. Pandemic H1N1 infection in pregnant women in the USA. Lancet 2009;374:429-430
48. Sakr Y, Madl C, Filipescu D, Moreno R, Groeneveld J, Artigas A, et al. Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med 2008; 34:1999-2009.
49. Centers for Disease Control and Prevention. Updated Interim Recommendations-HIV-Infected Adults and Adolescents. http://www.cdc.gov/h1n1flu/ guidance-HIV.htm.
50. Ginocchio CC, Zhang F, Manji R, Arora S, Bornfreund M, Falk L, et al. Evaluation of multiple test methods for the detection of the novel 2009 influenza A (H1N1) during the New York city outbreak. J Clin Virol 2009;45:191-195
51. Centers for Disease Control and Prevention. Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) virus-United States, 2009. MMWR 2009;58:826-829 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5830a2. htm.
52. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;361:728-729
53. Centers for Disease Control and Prevention. Performance of rapid influenza diagnostic tests during two school outbreaks of 2009 pandemic influenza A (H1N1) virus infection-connecticut, 2009. MMWR 2009;58:1029-1032 http://www.cdc.gov/ mmwr/preview/mmwrhtml/mm5837a1.htm.
54. Drexler JF, Helmer A, Kirberg H, Reber U, Panning M, Müller M, et al. Poor clinical sensitivity of rapid antigen test for influenza A pandemic (H1N1) 2009 virus. Emerg Infect Dis 2009;15:1662-1664
55. Centers for Disease Control and Prevention. Interim Recommendations for Clinical Use of Influenza Diagnostic Tests During the 2009-2010 Influenza Season. http://www.cdc.gov/ h1n1flu/guidance/diagnostic-tests.htm.
56. Panning M, Eickmann M, Landt O, Monazahian M, Olschläger S, Baumgarte S, et al. Detection of influenza A (H1N1)v virus by real-time RT-PCR. Euro Surveill 2009;14. pii: 19329. http://www.eurosurveillance.org/ViewArticle. aspx?ArticleIds 19329.
57. Berger A, Drosten Ch, Doerr HW, Stürmer M, Preiser W. Severe acute respiratory syndrome (SARS)-paradigm of an emerging viral infection. J Clin Virol 2004;29:13-22. (Pubitemid 37524081)
58. Centers for Disease Control and Prevention. Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season. http://www.cdc.gov/H1N1flu/ recommendations.htm.
59. Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002;186:1582-1588
60. Hayden FG, Belshe R, Villanueva C, Lanno R, Hughes C, Small I, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis 2004;189: 440-449
61. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Toronto invasive bacterial diseases network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007;45:1568-1575
62. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55(Suppl 1):i5-i21.
63. Taylor WR, Thinh BN, Anh GT, Horby P, Wertheim H, Lindegardh N, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 2008;3:e3410. doi:10.1371/journal.pone. 0003410.
64. Centers for Disease Control and Prevention. Novel influenza A (H1N1) virus infections in three pregnant women-United States, April-May 2009. MMWR 2009;58:497-500. http:// www.cdc.gov/mmwr/preview/mmwrhtml/mm5818a3.htm.
65. Centers for Disease Control and Prevention. Emergency use authorization of peramivir IV-fact sheet for health care providers. http://www.cdc.gov/ h1n1flu/eua/Final%20HCP%20Fact %20sheet%20Peramivir%20IV-CDC.pdf.
66. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009. NEJM 10.1056/nejmp0910479.
67. Centers for Disease Control and Prevention. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR 2009;58:433-435 http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm5816a6.htm.
68. World Health Organization. Pandemic (H1N1) 2009 briefing note 1-viruses resistant to oseltamivir (Tamiflu) identified. Weekly Epidemiological Record 2009;84:299-300. http:// www.who.int/wer/2009/wer8429/en/index.html.
69. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002;55:307-317
70. World Health Organization. Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009. Weekly Epidemiological Record 2009;84:453-458 http://www.who.int/wer/ 2009/wer8444/en/index.html.
71. Centers for Disease Control and Prevention. Oseltamivirresistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR 2009;58:893-896 http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5832a3.htm.
72. Centers for Disease Control and Prevention. Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR 2009; 58:1100-1101 http: / /www.cdc.gov/mmwr/ preview/mmwrhtml/ mm5839a3.htm.
73. European Medicines Agency. Pandemic influenza (H1N1) website. http://www.emea.europa.eu/influenza/vaccines/home.htm.
74. Australian Government Therapeutic Goods Administration. TGA approves vaccine against pandemic (H1N1) 2009 influenza. http://www.tga.gov.au/alerts/ medicines/h1n1vaccine.htm.
75. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response after one dose of a monovalent influenza A (H1N1) 2009 vaccine-preliminary report. N Engl J Med 2009;361. NEJM 10.1056/nejmoa0907413.
76. Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008;26:4057-4061
77. Centers for Disease Control. Use of influenza A (H1N1) 2009 monovalent vaccine-recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2009; 58(Early Release):1-8. http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr58e0821a1.htm.
78. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-1564
79. Ludwig B, Kraus FB, Allwinn R, Doerr HW, Preiser W. Viral zoonoses-a threat under control? Intervirology 2003;46:71-78